Cephalosporinsint Ermediates - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512242747

Publication Date:

December 5, 2024

Pages:

163

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Cephalosporin pharmaceutical intermediates are intermediate chemicals required in the synthesis of cephalosporin antibiotic chemicals.
The global market for Cephalosporinsint Ermediates was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Cephalosporinsint Ermediates was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cephalosporinsint Ermediates was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Cephalosporinsint Ermediates was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Cephalosporinsint Ermediates include Apotex, Esseti Farmaceutici, GSK, Lilly, Medochemie, LIVZON, Joincare Pharmaceutical Group Industry, Shandong Jincheng Pharmaceutical Group and Hebei Hejia Pharmaceutical Technology Group, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cephalosporinsint Ermediates, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Cephalosporinsint Ermediates by region & country, by Type, and by Application.
The Cephalosporinsint Ermediates market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cephalosporinsint Ermediates.
麻豆原创 Segmentation
By Company
Apotex
Esseti Farmaceutici
GSK
Lilly
Medochemie
LIVZON
Joincare Pharmaceutical Group Industry
Shandong Jincheng Pharmaceutical Group
Hebei Hejia Pharmaceutical Technology Group
Hebei Brant Pharmaceutical
Baomanbio
Merck
Seebio Biotech
Sichuan Kelun Pharmaceutical
Hebei Hejia Pharmaceutical Technology Group
ShenYuan ChemPharm
Zhejiang East-asia Pharmaceutical
The United Laboratories International Holdings Limited
Yili Chuanning Biotechnology
SHANGHAI PHARMA
Segment by Type:
Ceftriaxone Sodium Nonsterile
Ceftazidime Dihydrichloride Hydrate
Cefuroxime Free Acid
Cefodizime Free Acid
7-ACT
Descarbamcyl cefuroxime
Others
Segment by Application
Medicines and Health Products
Agriculture and Livestock
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cephalosporinsint Ermediates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Cephalosporinsint Ermediates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Cephalosporinsint Ermediates in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Cephalosporinsint Ermediates Product Introduction
1.2 Global Cephalosporinsint Ermediates 麻豆原创 Size Forecast
1.2.1 Global Cephalosporinsint Ermediates Sales Value (2019-2030)
1.2.2 Global Cephalosporinsint Ermediates Sales Volume (2019-2030)
1.2.3 Global Cephalosporinsint Ermediates Sales Price (2019-2030)
1.3 Cephalosporinsint Ermediates 麻豆原创 Trends & Drivers
1.3.1 Cephalosporinsint Ermediates Industry Trends
1.3.2 Cephalosporinsint Ermediates 麻豆原创 Drivers & Opportunity
1.3.3 Cephalosporinsint Ermediates 麻豆原创 Challenges
1.3.4 Cephalosporinsint Ermediates 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cephalosporinsint Ermediates Players Revenue Ranking (2023)
2.2 Global Cephalosporinsint Ermediates Revenue by Company (2019-2024)
2.3 Global Cephalosporinsint Ermediates Players Sales Volume Ranking (2023)
2.4 Global Cephalosporinsint Ermediates Sales Volume by Company Players (2019-2024)
2.5 Global Cephalosporinsint Ermediates Average Price by Company (2019-2024)
2.6 Key Manufacturers Cephalosporinsint Ermediates Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Cephalosporinsint Ermediates Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Cephalosporinsint Ermediates
2.9 Cephalosporinsint Ermediates 麻豆原创 Competitive Analysis
2.9.1 Cephalosporinsint Ermediates 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Cephalosporinsint Ermediates Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cephalosporinsint Ermediates as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Ceftriaxone Sodium Nonsterile
3.1.2 Ceftazidime Dihydrichloride Hydrate
3.1.3 Cefuroxime Free Acid
3.1.4 Cefodizime Free Acid
3.1.5 7-ACT
3.1.6 Descarbamcyl cefuroxime
3.1.7 Others
3.2 Global Cephalosporinsint Ermediates Sales Value by Type
3.2.1 Global Cephalosporinsint Ermediates Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cephalosporinsint Ermediates Sales Value, by Type (2019-2030)
3.2.3 Global Cephalosporinsint Ermediates Sales Value, by Type (%) (2019-2030)
3.3 Global Cephalosporinsint Ermediates Sales Volume by Type
3.3.1 Global Cephalosporinsint Ermediates Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Cephalosporinsint Ermediates Sales Volume, by Type (2019-2030)
3.3.3 Global Cephalosporinsint Ermediates Sales Volume, by Type (%) (2019-2030)
3.4 Global Cephalosporinsint Ermediates Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Medicines and Health Products
4.1.2 Agriculture and Livestock
4.2 Global Cephalosporinsint Ermediates Sales Value by Application
4.2.1 Global Cephalosporinsint Ermediates Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cephalosporinsint Ermediates Sales Value, by Application (2019-2030)
4.2.3 Global Cephalosporinsint Ermediates Sales Value, by Application (%) (2019-2030)
4.3 Global Cephalosporinsint Ermediates Sales Volume by Application
4.3.1 Global Cephalosporinsint Ermediates Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Cephalosporinsint Ermediates Sales Volume, by Application (2019-2030)
4.3.3 Global Cephalosporinsint Ermediates Sales Volume, by Application (%) (2019-2030)
4.4 Global Cephalosporinsint Ermediates Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Cephalosporinsint Ermediates Sales Value by Region
5.1.1 Global Cephalosporinsint Ermediates Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cephalosporinsint Ermediates Sales Value by Region (2019-2024)
5.1.3 Global Cephalosporinsint Ermediates Sales Value by Region (2025-2030)
5.1.4 Global Cephalosporinsint Ermediates Sales Value by Region (%), (2019-2030)
5.2 Global Cephalosporinsint Ermediates Sales Volume by Region
5.2.1 Global Cephalosporinsint Ermediates Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Cephalosporinsint Ermediates Sales Volume by Region (2019-2024)
5.2.3 Global Cephalosporinsint Ermediates Sales Volume by Region (2025-2030)
5.2.4 Global Cephalosporinsint Ermediates Sales Volume by Region (%), (2019-2030)
5.3 Global Cephalosporinsint Ermediates Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Cephalosporinsint Ermediates Sales Value, 2019-2030
5.4.2 North America Cephalosporinsint Ermediates Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Cephalosporinsint Ermediates Sales Value, 2019-2030
5.5.2 Europe Cephalosporinsint Ermediates Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Cephalosporinsint Ermediates Sales Value, 2019-2030
5.6.2 Asia Pacific Cephalosporinsint Ermediates Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Cephalosporinsint Ermediates Sales Value, 2019-2030
5.7.2 South America Cephalosporinsint Ermediates Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Cephalosporinsint Ermediates Sales Value, 2019-2030
5.8.2 Middle East & Africa Cephalosporinsint Ermediates Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cephalosporinsint Ermediates Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cephalosporinsint Ermediates Sales Value
6.2.1 Key Countries/Regions Cephalosporinsint Ermediates Sales Value, 2019-2030
6.2.2 Key Countries/Regions Cephalosporinsint Ermediates Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Cephalosporinsint Ermediates Sales Value, 2019-2030
6.3.2 United States Cephalosporinsint Ermediates Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cephalosporinsint Ermediates Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cephalosporinsint Ermediates Sales Value, 2019-2030
6.4.2 Europe Cephalosporinsint Ermediates Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cephalosporinsint Ermediates Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cephalosporinsint Ermediates Sales Value, 2019-2030
6.5.2 China Cephalosporinsint Ermediates Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cephalosporinsint Ermediates Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cephalosporinsint Ermediates Sales Value, 2019-2030
6.6.2 Japan Cephalosporinsint Ermediates Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cephalosporinsint Ermediates Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cephalosporinsint Ermediates Sales Value, 2019-2030
6.7.2 South Korea Cephalosporinsint Ermediates Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cephalosporinsint Ermediates Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cephalosporinsint Ermediates Sales Value, 2019-2030
6.8.2 Southeast Asia Cephalosporinsint Ermediates Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cephalosporinsint Ermediates Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cephalosporinsint Ermediates Sales Value, 2019-2030
6.9.2 India Cephalosporinsint Ermediates Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cephalosporinsint Ermediates Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Apotex
7.1.1 Apotex Company Information
7.1.2 Apotex Introduction and Business Overview
7.1.3 Apotex Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Apotex Cephalosporinsint Ermediates Product Offerings
7.1.5 Apotex Recent Development
7.2 Esseti Farmaceutici
7.2.1 Esseti Farmaceutici Company Information
7.2.2 Esseti Farmaceutici Introduction and Business Overview
7.2.3 Esseti Farmaceutici Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Esseti Farmaceutici Cephalosporinsint Ermediates Product Offerings
7.2.5 Esseti Farmaceutici Recent Development
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Introduction and Business Overview
7.3.3 GSK Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.3.4 GSK Cephalosporinsint Ermediates Product Offerings
7.3.5 GSK Recent Development
7.4 Lilly
7.4.1 Lilly Company Information
7.4.2 Lilly Introduction and Business Overview
7.4.3 Lilly Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Lilly Cephalosporinsint Ermediates Product Offerings
7.4.5 Lilly Recent Development
7.5 Medochemie
7.5.1 Medochemie Company Information
7.5.2 Medochemie Introduction and Business Overview
7.5.3 Medochemie Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Medochemie Cephalosporinsint Ermediates Product Offerings
7.5.5 Medochemie Recent Development
7.6 LIVZON
7.6.1 LIVZON Company Information
7.6.2 LIVZON Introduction and Business Overview
7.6.3 LIVZON Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.6.4 LIVZON Cephalosporinsint Ermediates Product Offerings
7.6.5 LIVZON Recent Development
7.7 Joincare Pharmaceutical Group Industry
7.7.1 Joincare Pharmaceutical Group Industry Company Information
7.7.2 Joincare Pharmaceutical Group Industry Introduction and Business Overview
7.7.3 Joincare Pharmaceutical Group Industry Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Joincare Pharmaceutical Group Industry Cephalosporinsint Ermediates Product Offerings
7.7.5 Joincare Pharmaceutical Group Industry Recent Development
7.8 Shandong Jincheng Pharmaceutical Group
7.8.1 Shandong Jincheng Pharmaceutical Group Company Information
7.8.2 Shandong Jincheng Pharmaceutical Group Introduction and Business Overview
7.8.3 Shandong Jincheng Pharmaceutical Group Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Shandong Jincheng Pharmaceutical Group Cephalosporinsint Ermediates Product Offerings
7.8.5 Shandong Jincheng Pharmaceutical Group Recent Development
7.9 Hebei Hejia Pharmaceutical Technology Group
7.9.1 Hebei Hejia Pharmaceutical Technology Group Company Information
7.9.2 Hebei Hejia Pharmaceutical Technology Group Introduction and Business Overview
7.9.3 Hebei Hejia Pharmaceutical Technology Group Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Hebei Hejia Pharmaceutical Technology Group Cephalosporinsint Ermediates Product Offerings
7.9.5 Hebei Hejia Pharmaceutical Technology Group Recent Development
7.10 Hebei Brant Pharmaceutical
7.10.1 Hebei Brant Pharmaceutical Company Information
7.10.2 Hebei Brant Pharmaceutical Introduction and Business Overview
7.10.3 Hebei Brant Pharmaceutical Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Hebei Brant Pharmaceutical Cephalosporinsint Ermediates Product Offerings
7.10.5 Hebei Brant Pharmaceutical Recent Development
7.11 Baomanbio
7.11.1 Baomanbio Company Information
7.11.2 Baomanbio Introduction and Business Overview
7.11.3 Baomanbio Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Baomanbio Cephalosporinsint Ermediates Product Offerings
7.11.5 Baomanbio Recent Development
7.12 Merck
7.12.1 Merck Company Information
7.12.2 Merck Introduction and Business Overview
7.12.3 Merck Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Merck Cephalosporinsint Ermediates Product Offerings
7.12.5 Merck Recent Development
7.13 Seebio Biotech
7.13.1 Seebio Biotech Company Information
7.13.2 Seebio Biotech Introduction and Business Overview
7.13.3 Seebio Biotech Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Seebio Biotech Cephalosporinsint Ermediates Product Offerings
7.13.5 Seebio Biotech Recent Development
7.14 Sichuan Kelun Pharmaceutical
7.14.1 Sichuan Kelun Pharmaceutical Company Information
7.14.2 Sichuan Kelun Pharmaceutical Introduction and Business Overview
7.14.3 Sichuan Kelun Pharmaceutical Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Sichuan Kelun Pharmaceutical Cephalosporinsint Ermediates Product Offerings
7.14.5 Sichuan Kelun Pharmaceutical Recent Development
7.15 Hebei Hejia Pharmaceutical Technology Group
7.15.1 Hebei Hejia Pharmaceutical Technology Group Company Information
7.15.2 Hebei Hejia Pharmaceutical Technology Group Introduction and Business Overview
7.15.3 Hebei Hejia Pharmaceutical Technology Group Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Hebei Hejia Pharmaceutical Technology Group Cephalosporinsint Ermediates Product Offerings
7.15.5 Hebei Hejia Pharmaceutical Technology Group Recent Development
7.16 ShenYuan ChemPharm
7.16.1 ShenYuan ChemPharm Company Information
7.16.2 ShenYuan ChemPharm Introduction and Business Overview
7.16.3 ShenYuan ChemPharm Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.16.4 ShenYuan ChemPharm Cephalosporinsint Ermediates Product Offerings
7.16.5 ShenYuan ChemPharm Recent Development
7.17 Zhejiang East-asia Pharmaceutical
7.17.1 Zhejiang East-asia Pharmaceutical Company Information
7.17.2 Zhejiang East-asia Pharmaceutical Introduction and Business Overview
7.17.3 Zhejiang East-asia Pharmaceutical Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Zhejiang East-asia Pharmaceutical Cephalosporinsint Ermediates Product Offerings
7.17.5 Zhejiang East-asia Pharmaceutical Recent Development
7.18 The United Laboratories International Holdings Limited
7.18.1 The United Laboratories International Holdings Limited Company Information
7.18.2 The United Laboratories International Holdings Limited Introduction and Business Overview
7.18.3 The United Laboratories International Holdings Limited Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.18.4 The United Laboratories International Holdings Limited Cephalosporinsint Ermediates Product Offerings
7.18.5 The United Laboratories International Holdings Limited Recent Development
7.19 Yili Chuanning Biotechnology
7.19.1 Yili Chuanning Biotechnology Company Information
7.19.2 Yili Chuanning Biotechnology Introduction and Business Overview
7.19.3 Yili Chuanning Biotechnology Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.19.4 Yili Chuanning Biotechnology Cephalosporinsint Ermediates Product Offerings
7.19.5 Yili Chuanning Biotechnology Recent Development
7.20 SHANGHAI PHARMA
7.20.1 SHANGHAI PHARMA Company Information
7.20.2 SHANGHAI PHARMA Introduction and Business Overview
7.20.3 SHANGHAI PHARMA Cephalosporinsint Ermediates Sales, Revenue and Gross Margin (2019-2024)
7.20.4 SHANGHAI PHARMA Cephalosporinsint Ermediates Product Offerings
7.20.5 SHANGHAI PHARMA Recent Development
8 Industry Chain Analysis
8.1 Cephalosporinsint Ermediates Industrial Chain
8.2 Cephalosporinsint Ermediates Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cephalosporinsint Ermediates Sales Model
8.5.2 Sales Channel
8.5.3 Cephalosporinsint Ermediates Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Apotex
Esseti Farmaceutici
GSK
Lilly
Medochemie
LIVZON
Joincare Pharmaceutical Group Industry
Shandong Jincheng Pharmaceutical Group
Hebei Hejia Pharmaceutical Technology Group
Hebei Brant Pharmaceutical
Baomanbio
Merck
Seebio Biotech
Sichuan Kelun Pharmaceutical
Hebei Hejia Pharmaceutical Technology Group
ShenYuan ChemPharm
Zhejiang East-asia Pharmaceutical
The United Laboratories International Holdings Limited
Yili Chuanning Biotechnology
SHANGHAI PHARMA

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.